Hepion director granted 299K options at $0.08

Hepion Pharmaceuticals, Inc. (HEPA) reported that director Danina Fisher received a grant of stock options to acquire 299,000 shares of common stock.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that director Danina Fisher received a grant of stock options to acquire 299,000 shares of common stock. The options have an exercise price of $0.08 per share, become exercisable on August 19, 2027, and expire on August 19, 2036. Following this grant, Fisher holds 299,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 299,000 shares

Grant/Award 1 txn

Insider Fisher Danina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	299,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 299,000 contracts (Direct)

Key Figures

Stock options granted: 299,000 options Exercise price: $0.08 per share Underlying shares: 299,000 shares +3 more

6 metrics

Stock options granted 299,000 options Grant of stock options to director Danina Fisher on August 19, 2026

Exercise price $0.08 per share Conversion or exercise price for the granted stock options

Underlying shares 299,000 shares Common stock underlying the granted stock options

Exercise date August 19, 2027 Date on which the stock options become exercisable

Expiration date August 19, 2036 Expiration of the stock options held by Danina Fisher

Holdings after transaction 299,000 derivative securities Total derivative securities owned directly by Danina Fisher after the grant

Key Terms

Stock Options, exercise price, expiration date, underlying security

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price: "0.0800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-08-19""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HEPA director Danina Fisher report on this Form 4?

Danina Fisher reported a grant of stock options relating to 299,000 shares of Hepion Pharmaceuticals, Inc. common stock. The options were acquired as a grant or award and are held directly.

How many HEPA shares are covered by the new stock options?

The new stock option grant covers 299,000 shares of Hepion Pharmaceuticals, Inc. common stock as the underlying security. After this grant, Fisher holds 299,000 derivative securities directly.

What is the exercise price of Danina Fisher’s HEPA stock options?

The stock options granted to Danina Fisher have an exercise price of $0.08 per share. This is the price per share at which the options allow her to acquire Hepion Pharmaceuticals, Inc. common stock once exercisable.

When do Danina Fisher’s HEPA stock options vest and expire?

The options become exercisable on August 19, 2027 and have an expiration date of August 19, 2036. After the expiration date, the options can no longer be exercised for Hepion Pharmaceuticals, Inc. shares.

Is this HEPA Form 4 transaction a buy or sell of common stock?

The Form 4 reports an acquisition of derivative securities through a grant of stock options. It does not report a market purchase or sale of Hepion Pharmaceuticals, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:32 PM EDT Accepted by SEC EDGAR 08/21/2026 - 04:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisher Danina

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.08	08/19/2026		A		299,000		08/19/2027	08/19/2036	Common Stock	299,000	$0	299,000	D

Explanation of Responses:

	/s/ Danina Fisher	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)